Advertisement

CNS Drugs

, Volume 32, Issue 5, pp 421–435 | Cite as

Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review

  • MacKenzie R. Peltier
  • Mehmet Sofuoglu
Review Article
  • 93 Downloads

Abstract

Substance use disorders (SUDs) remain problematic as many individuals are untreated or do not benefit from the currently available interventions. Thus, there is an urgent need to develop novel pharmacological interventions to treat SUDs. Evidence suggests that the female sex hormone, progesterone, attenuates the craving for and the euphoric effects of drugs of abuse. Research to date has demonstrated that progesterone may modulate responses to drugs of abuse and may have utility as a novel treatment for SUDs. A literature search was conducted to identify and examine studies that administered exogenous progesterone. Sixteen publications were identified, exploring the utility of exogenous progesterone or its metabolite, allopregnanolone, among a range of substances, including amphetamines (one study), benzodiazepines (one study), cocaine (nine studies), and tobacco/nicotine (five studies). Results indicated that exogenous progesterone and, its metabolite allopregnanolone, demonstrated preliminary efficacy as a treatment for substance use in both men and women. Notably, progesterone appears to target negative affect and augment cognitive functioning, especially among female substance users. Additional research is needed to explore the potential use of exogenous progesterone and allopregnanolone in the treatment of SUDs, including that associated with alcohol and opioids, but considering the current promising findings, exogenous progesterone and allopregnanolone may have utility as novel pharmacological treatments for SUDs.

Notes

Compliance with Ethical Standards

Funding

Article preparation was supported by the Veterans Affairs New England Mental Illness Research, Education and Clinical Center, as well as a National Institute of Drug Abuse Training Grant T32-DA007238.

Conflict of interest

MacKenzie Peltier and Mehmet Sofuoglu have no conflicts of interest directly relevant to the content of this article.

References

  1. 1.
    United Nations Office on Drugs and Crime (UNODC). World drug report 2017. 2017. Available from: http://www.unodc.org/wdr2017/. Accessed 27 Dec 2017.
  2. 2.
    GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210.Google Scholar
  3. 3.
    National Institute of Drug Abuse (NIDA). Health consequences of drug misuse. 2017. Available from: https://www.drugabuse.gov/related-topics/health-consequences-drug-misuse. Accessed 6 Oct 2017.
  4. 4.
    Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS. Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions. III. JAMA Psychiatry. 2016;73:39–47.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Evans S, Haney M, Foltin R. The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology. 2002;159:397–406.PubMedGoogle Scholar
  6. 6.
    Moran-Santa Maria MM, Flanagan J, Brady K. Ovarian hormones and drug abuse. Curr Psychiatry Rep. 2014;16:511.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Sofuoglu M, Mouratidis M, Mooney M. Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology. 2011;36:123–32.PubMedGoogle Scholar
  8. 8.
    Sofuoglu M, Dudish-Poulsen S, Nelson D, Pentel PR, Hatsukami DK. Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharm. 1999;7:274–83.Google Scholar
  9. 9.
    Lynch WJ, Sofuoglu M. Role of progesterone in nicotine addiction: evidence from initiation to relapse. Exp Clin Psychopharm. 2010;18:451–61.Google Scholar
  10. 10.
    Becker JB. Sex differences in addiction. Dial Clin Neurosci. 2016;18:395–402.Google Scholar
  11. 11.
    Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinol. 2008;29:36–47.PubMedGoogle Scholar
  12. 12.
    Riley AL, Hempel BJ, Clasen MM. Sex as a biological variable: drug use and abuse. Physiol Behav. 2018;187:79–96.PubMedGoogle Scholar
  13. 13.
    Lynch WJ, Carroll ME. Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. Psychopharmacology. 1999;144:77–82.PubMedGoogle Scholar
  14. 14.
    Priddy BM, Carmack SA, Thomas LC, Vendruscolo JCM, Koob GF, Vendruscolo LF. Sex, strain, and estrous cycle influences on alcohol drinking in rats. Pharmacol Biochem Behav. 2017;152:6–67.Google Scholar
  15. 15.
    Randall PA, Stewart RT, Besheer J. Sex differences in alcohol self-administration and relapse-like behavior in Long-Evans rats. Pharmacol Biochem Behav. 2017;156:1–9.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Cicero TJ, Aylward SC, Meyer ER. Gender differences in the intravenous self-administration of mu opiate agonists. Pharmacol Biochem Behav. 2003;74:541–9.PubMedGoogle Scholar
  17. 17.
    Donny E, Caggiula A, Rowell P, Gharib M, Maldovan V, Booth S, Mielke MM, Hoffman A, Mccallum S. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology. 2000;151:392–405.PubMedGoogle Scholar
  18. 18.
    Roth ME, Cosgrove KP, Carroll ME. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev. 2004;28:533–46.PubMedGoogle Scholar
  19. 19.
    Lynch WJ, Carroll ME. Reinstatement of cocaine self-administration in rats: sex differences. Psychopharmacology. 2000;148:196–200.PubMedGoogle Scholar
  20. 20.
    Lynch WJ, Taylor JR. Sex differences in the behavioral effects of 24-h access to cocaine under a discrete trial procedure. Neuropsychopharmacology. 2004;29:943–51.PubMedGoogle Scholar
  21. 21.
    Bertholomey ML, Nagarajan V, Torregrossa MM. Sex differences in reinstatement of alcohol seeking in response to cues and yohimbine in rats with and without a history of adolescent corticosterone exposure. Psychopharmacology. 2016;233:2277–87.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Feltenstein MW, Henderson AR, See RE. Enhancement of cue-induced reinstatement of cocaine-seeking in rats by yohimbine: sex differences and the role of the estrous cycle. Psychopharmacology. 2011;216:53–62.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Fuchs RA, Evans KA, Mehta RH, Case JM, See RE. Influence of sex and estrous cyclicity on conditioned cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology. 2004;179:662–72.Google Scholar
  24. 24.
    Holtz NA, Lozama A, Prisinzano TE, Carroll ME. Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone. Drug Alcohol Depend. 2012;120:233–7.PubMedGoogle Scholar
  25. 25.
    Gentile NE, Andrewkanic JD, Karwoski TE, Czambel RK, Rubin RT, Rhodes ME. Sexually diergic hypothalamic–pituitary–adrenal (HPA) responses to single-dose nicotine, continuous nicotine infusion, and nicotine withdrawal by mecamylamine in rats. Brain Res Bull. 2011;85:145–52.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hart-Hargrove LC, Dow-Edwards DL. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav Brain Res. 2012;231:48–59.Google Scholar
  27. 27.
    Kerstetter KA, Aguilar VR, Parrish AB, Kippin TE. Protracted time-dependent increases in cocaine-seeking behavior during cocaine withdrawal in female relative to male rats. Psychopharmacology. 2008;198:63–75.PubMedGoogle Scholar
  28. 28.
    Bisagno V, Fergunson D, Luine VN. Chronic D-amphetamine induces sexually dimorphic effects on locomotion, recognition memory, and brain monoamines. Pharmacol Biochem Behav. 2003;73:859–67.Google Scholar
  29. 29.
    Cicero TJ, Nock B, Meyer ER. Gender-linked differences in the expression of physical dependence in the rat. Pharmacol Biochem Behav. 2002;72:691–7.PubMedGoogle Scholar
  30. 30.
    Reilly W, Koirala B, Devaud LL. Sex differences in acoustic startle responses and seizure thresholds between ethanol-withdrawn male and female rats. Alcohol Alcohol. 2008;44:561–6.Google Scholar
  31. 31.
    Varlinskay E, Spear LP. Acute ethanol withdrawal (hangover) and social behavior in adolescent and adult male and female Sprague–Dawley rats. Alcohol Clin Exp Res. 2004;28:40–50.Google Scholar
  32. 32.
    McHugh RK, Wigderson S, Greenfield SF. Epidemiology of substance use in reproductive-age women. Obstet Gynecol Clin North Am. 2014;41:177–89.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults: United States, 2005–2015. Morb Mortal Wkly Rep. 2016;65:1205–11.Google Scholar
  34. 34.
    Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72:757–66.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Lewis B, Hoffman LA, Nixon SJ. Sex differences in drug use among polysubstance users. Drug Alcohol Depend. 2014;145:127–33.PubMedGoogle Scholar
  36. 36.
    Lewis B, Nixon SJ. Characterizing gender differences in treatment seekers. Alcoholism Clin Exp Res. 2014;38:275–84.Google Scholar
  37. 37.
    Perkins KA. Smoking cessation in women. CNS Drugs. 2001;15:391–411.PubMedGoogle Scholar
  38. 38.
    Substance Abuse and Mental Health Service Administration (SAMSHA). Chapter 3. Physiological effects of alcohol, drugs, and tobacco on women. In: Substance abuse treatment: addressing the specific needs of women (Treatment Improvement Protocol, No. 5). 2009. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83244/. Accessed 5 May 2018.
  39. 39.
    National Institute of Drug Abuse (NIDA). Substance use in women. 2016. Available from: https://www.drugabuse.gov/publications/research-reports/substance-use-in-women. Accessed 9 Oct 2017.
  40. 40.
    Terplan M, McNamara EJ, Chisolm MS. Pregnant and non-pregnant women with substance use disorders: the gap between treatment need and receipt. J Addict Dis. 2012;31:342–9.PubMedGoogle Scholar
  41. 41.
    Hudson A, Stamp JA. Ovarian hormones and propensity to drug relapse: a review. Neurosci Biobehav Rev. 2011;35:427–36.PubMedGoogle Scholar
  42. 42.
    Perkins KA. Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharm. 1996;4:166–77.Google Scholar
  43. 43.
    Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin N Am. 2010;33:339–55.Google Scholar
  44. 44.
    Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. Nicotine Tob Res. 2015;17:486–95.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Weinberger AH, McKee SA, George TP. Smoking cue reactivity in adult smokers with and without depression: a pilot study. Am J Addict. 2012;1:136–44.Google Scholar
  46. 46.
    Potenza MN, Hong KA, Lacadie CM, Fulbright RK, Tuit KL, Sinha R. Neural correlates of stress-induced and cue-induced drug craving: influences of sex and cocaine dependence. Am J Psychiatry. 2012;169:406–14.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Cosgrove KP, Wang S, Kim S, McGovern E, Nabulsi N, Gao H, Labaree D, Tagare HD, Sullivan JM, Morris ED. Sex differences in the brain’s dopamine signature of cigarette smoking. J Neurosci. 2014;34:16851–5.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Saladin ME, Gray KM, Carpenter MJ, LaRowe SD, DeSantis SM, Upadhyaya HP. Gender differences in craving and cue reactivity to smoking and negative affect/stress cues. Am J Addict. 2012;21(3):210–20.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Nakajima M, Al’Absi M. Predictors of risk for smoking relapse in men and women: a prospective examination. Psychol Addict Behav. 2012;26(3):633–7.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Husky MM, Mazure CM, Paliwal P, McKee SA. Gender differences in the comorbidity of smoking behavior and major depression. Drug Alcohol Depend. 2008;93(1–2):176–9.PubMedGoogle Scholar
  51. 51.
    Weinberger AH, McKee SA. Gender sifferences in smoking following an implicit mood induction. Nicotine Tob Res. 2012;14(5):621–5.PubMedGoogle Scholar
  52. 52.
    Perkins KA, Karlitz JL, Kunkle N. Sex differences in subjective responses to moderate versus very low nicotine content cigarettes. Nicotine Tob Res. 2017.  https://doi.org/10.1093/ntr/ntx205. Epub ahead of print.
  53. 53.
    Hartwell EE, Ray LA. Sex moderates stress reactivity in heavy drinkers. Addict Behav. 2013;38:2643–6.PubMedGoogle Scholar
  54. 54.
    DeVito EE, Herman AI, Waters AJ, Valentine GW, Sofuoglu M. Subjective, physiological, and cognitive responses to intravenous nicotine: effects of sex and menstrual cycle phase. Neuropsychopharmacology. 2014;39:1431–40.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Sofuoglu M, Mitchell E, Mooney M. Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. Hum Psychopharmacol (Berl). 2009;24:559–64.Google Scholar
  56. 56.
    Oettel M, Mukhopadhyay AK. Progesterone: the forgotten hormone in men? Aging Male. 2004;7:236–57.PubMedGoogle Scholar
  57. 57.
    Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M. Progesterone and allopregnanolone in the central nervous system: response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol. 2015;146:48–61.PubMedGoogle Scholar
  58. 58.
    Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res. 2010;186:113–37.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Singh M, Su C, Ng S. Non-genomic mechanisms of progesterone action in the brain. Front Neurosci. 2013;7:159.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Schumacher M, Coirini H, Robert F, Guennoun R, El-Etr M. Genomic and membrane actions of progesterone: Implications for reproductive physiology and behavior. Behav Brain Res. 1999;1:37–52.Google Scholar
  61. 61.
    Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson I. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162:311–27.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol. 2007;74:1155–63.PubMedGoogle Scholar
  63. 63.
    Gangitano D, Salas R, Teng Y, Perez E, De Biasi M. Progesterone modulation of α5 nAChR subunits influences anxiety-related behavior during estrus cycle. Genes Brain Behav. 2009;8:398–406.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Pandya A, Yakel JL. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors. Biochem Pharmacol. 2011;82:952–8.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J, Lopez JA. Novel progesterone receptors: neural localization and possible functions. Front Neurosci. 2013;7:164.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during ageing: from periphery to brain. Trends Mol Med. 2013;19:197–209.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Pigott TA, Walker MH, Teitelbaum SA, Lu C. Sex differences and neurotransmitter systems in addiction. In: Brady KT, Back SE, Greenfield SF, editors. Women and addiction: a comprehensive handbook. New York (NY): The Guilford Press; 2009. p. 99–117.Google Scholar
  68. 68.
    Hall JE. Neuroendocrine control of the menstrual cycle. In: Strauss JF. Barbieri RL, editors. Yen and Jaffe’s reproductive endocrinology, physiology, pathology, and clinical management, 6th edn. Philadelphia (PA): Elsevier; 2009. p. 139–54.Google Scholar
  69. 69.
    Carmina E, Lobo RA. Evaluation of hormonal status. In: Strauss JF. Barbieri RL, editors. Yen and Jaffe’s reproductive endocrinology, physiology, pathology, and clinical management, 6th ed. Philadelphia (PA): Sauders Elsevier; 2009: p. 801–24.Google Scholar
  70. 70.
    Knobil E, Neill JD. Knobil and Neill’s physiology of reproduction. 3rd ed. Boston (MA): Elsevier; 2006.Google Scholar
  71. 71.
    Sun J, Walker AJ, Dean B, Van den Buuse M, Gogos A. Progesterone: the neglected hormone in schizophrenia? A focus on progesterone–dopamine interactions. Psychoneuroendocrinology. 2016;74:126–40.PubMedGoogle Scholar
  72. 72.
    Lynch WJ, Roth ME, Mickelberg JL, Carroll ME. Role of estrogen in the acquisition of intravenously self-administered cocaine in female rats. Pharmacol Biochem Behav. 2001;68:641–6.PubMedGoogle Scholar
  73. 73.
    Jackson LR, Robinson TE, Becker JB. Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. Neuropsychopharmacology. 2005;31:129–38.Google Scholar
  74. 74.
    Anker JJ, Larson EB, Gliddon LA, Carroll ME. Effects of progesterone on the reinstatement of cocaine-seeking behavior in female rats. Exp Clin Psychopharm. 2007;15:472–80.Google Scholar
  75. 75.
    Mello NK. Hormones, nicotine, and cocaine: clinical studies. Horm Behav. 2010;58:57–71.PubMedGoogle Scholar
  76. 76.
    Smethells JR, Swalve NL, Eberly LE, Carroll ME. Sex differences in the reduction of impulsive choice (delay discounting) for cocaine in rats with atomoxetine and progesterone. Psychopharmacology. 2016;233:2999–3008.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Carroll ME, Anker JJ. Sex differences and ovarian hormones in animal models of drug dependence. Horm Behav. 2010;58:44–56.PubMedGoogle Scholar
  78. 78.
    Allen SS, Bade T, Center B, Finstad D, Hatsukami D. Menstrual phase effects on smoking relapse. Addiction. 2008;103:809–21.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Carpenter MJ, Saladin ME, Leinbach AS, Larowe SD, Upadhyaya HP. Menstrual phase effects on smoking cessation: a pilot feasibility study. Res J Women Health. 2008;17:293–301.Google Scholar
  80. 80.
    Franklin TR, Allen SS. Influence of menstrual cycle phase on smoking cessation treatment outcome: a hypothesis regarding the discordant findings in the literature. Addiction. 2009;104:1941–2.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Allen AM, Allen SS, Lunos S, Pomerleau CS. Severity of withdrawal symptomatology in follicular versus luteal quitters: the combined effects of menstrual phase and withdrawal on smoking cessation outcome. Addict Behav. 2010;35:549–52.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Allen AM, Al’Absi M, Lando H, Allen SS. Allopregnanolone association with psychophysiological and cognitive functions during acute smoking abstinence in premenopausal women. Exp Clin Psychopharm. 2015;23:22–8.Google Scholar
  83. 83.
    Saladin ME, McClure EA, Baker NL, Carpenter MJ, Ramakrishnan V, Hartwell KJ, Gray KM. Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy. Nicotine Tob Res. 2015;17:398–406.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Allen AM, Lunos S, Heishman SJ, Al’Absi M, Hatsukami D, Allen SS. Subjective response to nicotine by menstrual phase. Addict Behav. 2015;43:50–3.PubMedGoogle Scholar
  85. 85.
    Moran-Santa Maria MM, Sherman BJ, Brady K, Baker NL, Hyer JM, Ferland C, McRae-Clark AL. Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women. Pharmacol Biochem Behav. 2018;165:63–9.PubMedGoogle Scholar
  86. 86.
    White TL, Justice AJ, de Wit H. Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002;73:729–41.PubMedGoogle Scholar
  87. 87.
    Franklin TR, Jagannathan K, Wetherill RR, Johnson B, Kelly S, Langguth J, Mumma J, Childress AR. Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res. 2015;17:390–7.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Fox H, Sinha R. Stress, neuroendocrine response, and addiction in women. In: Brady KT, Back SE, Greenfield SF, editors. Women and addiction: a comprehensive handbook. New York (NY): The Guilford Press; 2009. p. 65–83.Google Scholar
  89. 89.
    Blume AW, Marlatt GA. The role of executive cognitive functions in changing substance use: what we know and what we need to know. Ann Behav Med. 2009;37:117–25.PubMedGoogle Scholar
  90. 90.
    Streeter CC, Terhune DB, Whitfield TH, et al. Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals. Neuropsychopharmacology. 2007;33:827–36.PubMedGoogle Scholar
  91. 91.
    Berent-Spillson A, Briceno E, Pinsky A, et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology. 2015;59:25–36.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Solís-Ortiz S, Corsi-Cabrera M. Sustained attention is favored by progesterone during early luteal phase and visuo-spatial memory by estrogens during ovulatory phase in young women. Psychoneuroendocrinology. 2008;33:989–98.PubMedGoogle Scholar
  93. 93.
    Sofuoglu M, Babb DA, Hatsukami DK. Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women. Pharmacol Biochem Behav. 2001;69:299–304.PubMedGoogle Scholar
  94. 94.
    Evans SM, Foltin RW. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology. 2006;31:659–74.PubMedGoogle Scholar
  95. 95.
    Sofuoglu M, Babb DA, Hatsukami DK. Effects of progesterone treatment on smoked cocaine response in women. Pharmacol Biochem Behav. 2002;72:431–5.PubMedGoogle Scholar
  96. 96.
    Sofuoglu M, Mitchell E, Kosten TR. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav. 2004;78:699–705.PubMedGoogle Scholar
  97. 97.
    Reed SC, Levin FR, Evans SM. The effects of progesterone pretreatment on the response to oral d-amphetamine in women. Horm Behav. 2010;58:533–43.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Fox HC, Sofuoglu M, Morgan PT, Tuit KL, Sinha R. The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: impact of gender and cue type. Psychoneuroendocrinology. 2013;38:1532–44.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Milivojevic V, Fox HC, Sofuoglu M, Covault J, Sinha R. Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women. Psychoneuroendocrinology. 2016;65:44–53.PubMedGoogle Scholar
  100. 100.
    Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA. Progesterone for smoking relapse prevention following delivery: a pilot, randomized, double-blind study. Psychoneuroendocrinology. 2017;86:96–103.PubMedGoogle Scholar
  101. 101.
    Reed SC, Evans SM, Bedi G, Rubin E, Foltin RW. The effects of oral micronized progesterone on smoked cocaine self-administration in women. Horm Behav. 2011;59:227–35.PubMedGoogle Scholar
  102. 102.
    Sofuoglu M, Poling J, Gonzale G, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Psychopharmacology. 2007;15:453–60.Google Scholar
  103. 103.
    Yonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone reduces cocaine use in postpartum women with a cocaine use disorder: a randomized, double-blind study. Lancet Psychiatry. 2014;1:360–7.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Allen SS, Allen AM, Lunos S, Tosun N. Progesterone and postpartum smoking relapse: a pilot double-blind placebo-controlled randomized trial. Nicotine Tob Res. 2016;18:2145–53.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Schweize E, Case WG, Garcia-Espana F, Greenblatt DJ, Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology. 1995;117:424–9.Google Scholar
  106. 106.
    Milivojevic V, Sinha R, Morgan P, Sofuoglu M, Fox H. Effects of endogenous and exogenous progesterone on emotional intelligence in cocaine dependent men and women who also abuse alcohol. Hum Psychopharmacol. 2014;29:589–98.PubMedPubMedCentralGoogle Scholar
  107. 107.
    McHugh RK, DeVito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013;45:38–43.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Saladin ME, Gray KM, Carpenter MJ, LaRowe SD, DeSantis SM, Upadhyaya HP. Gender differences in craving and cue reactivity to smoking and negative affect/stress cues. Am J Addict. 2012;21:210–20.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Weng J, Chung B. Nongenomic actions of neurosteroid pregnenolone and its metabolites. Steroids. 2016;111:54–9.PubMedGoogle Scholar
  110. 110.
    Sinha R, Jastreboff AM. Stress as a common risk factor for obesity and addiction. Biol Psychiatry. 2013;73(9):827–35.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Hellgren C, Akerud H, Skalkidou A, Backstrom T, Sundstrom-Poromaa I. Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology. 2014;69:147–53.PubMedGoogle Scholar
  112. 112.
    Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer- Brody S. Brexanolone (SAGE-547 injection) in post-partum depression: a randomized controlled trial. Lancet. 2017;390:480–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychiatryYale School of MedicineNew HavenUSA
  2. 2.VA Connecticut Healthcare SystemWest HavenUSA

Personalised recommendations